Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Rating) in a report released on Sunday. The brokerage set a “sell” rating on the stock.

Several other equities research analysts have also issued reports on MBRX. Roth Mkm reaffirmed a “buy” rating and set a $16.00 price target on shares of Moleculin Biotech in a report on Tuesday, April 18th. Oppenheimer restated an “outperform” rating and issued a $5.00 price target on shares of Moleculin Biotech in a research report on Friday, March 24th.

Moleculin Biotech Stock Performance

MBRX stock opened at $0.63 on Friday. The company has a market capitalization of $18.62 million, a PE ratio of -0.59 and a beta of 1.99. Moleculin Biotech has a 52 week low of $0.58 and a 52 week high of $1.94. The company’s 50-day simple moving average is $0.85 and its 200 day simple moving average is $1.08.

Moleculin Biotech (NASDAQ:MBRX – Get Rating) last released its earnings results on Wednesday, March 22nd. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.04. On average, analysts forecast that Moleculin Biotech will post -1.09 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of MBRX. Charles Schwab Investment Management Inc. acquired a new position in shares of Moleculin Biotech during the 4th quarter valued at $39,000. Renaissance Technologies LLC increased its stake in Moleculin Biotech by 79.3% during the 1st quarter. Renaissance Technologies LLC now owns 59,900 shares of the company’s stock valued at $107,000 after purchasing an additional 26,500 shares in the last quarter. Finally, State Street Corp increased its stake in Moleculin Biotech by 19.2% during the 1st quarter. State Street Corp now owns 71,397 shares of the company’s stock valued at $127,000 after purchasing an additional 11,497 shares in the last quarter. Institutional investors and hedge funds own 10.43% of the company’s stock.

Moleculin Biotech Company Profile

(Get Rating)

Moleculin Biotech, Inc is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.